Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 49-58

  Kiesslich, Tobias ^a   Alinger, Beate ^a   Wolkersdörfer, Gernot W ^a   Ocker, Matthias ^b   Neureiter, Daniel ^a   Berr, Frieder ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Biliary tract cancer; Differentiation; Pathway inhibition; Proliferation; Wnt signalling pathway

Indexed keywords

BETA CATENIN; CYCLIN D1; CYTOKERATIN 18; CYTOKERATIN 8; CYTOPLASM PROTEIN; KI 67 ANTIGEN; UVOMORULIN; VIMENTIN; WNT PROTEIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ARTICLE; BILIARY TRACT CANCER; CANCER CELL CULTURE; CANCER STAGING; CANCER TISSUE; CELL CYCLE; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT;

ANIMALS; BILIARY TRACT NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 74549225756     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000474     Document Type: Article

References (54)

1. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
2. Lazaridis KN and Gores GJ: Cholangiocarcinoma. Gastroenterology 128: 1655-1667, 2005.
3. Kiesslich T, Wolkersdorfer G, Neureiter D, Salmhofer H and Berr F: Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci 8: 23-30, 2009.
4. Verslype C, Prenen H and Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 10: 164-167, 2008.
5. Bailey JM, Singh PK and Hollingsworth MA: Cancer metastasis facilitated by developmental pathways: sonic hedgehog, notch, and bone morphogenic proteins. J Cell Biochem 102: 829-839, 2007.
6. Kelleher FC, Fennelly D and Rafferty M: Common critical pathways in embryogenesis and cancer. Acta Oncol 45: 375-388, 2006.
7. Kolligs FT, Bommer G and Goke B: Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66: 131-144, 2002.
8. Lees C, Howie S, Sartor RB and Satsangi J: The hedgehog signalling pathway in the gastrointestinal tract: implications for development, homeostasis, and disease. Gastroenterology 129: 1696-1710, 2005.
9. Clevers H: Inflating cell numbers by Wnt. Mol Cell 10: 1260-1261, 2002.
10. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
11. Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221, 2003.
12. Doucas H, Garcea G, Neal CP, Manson MM and Berry DP: Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 41: 365-379, 2005.
13. Huang H and He X: Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20: 119-125, 2008.
14. Miller JR: The Wnts. Genome Biol 3: 3001.1-3001.15, 2002.
15. The Wnt Homepage by 1997-2008 Roel Nusse; URL:http://www.stanford.edu/ ~rnusse/wntwindow.html.
16. Ewan KB and Dale TC: The potential for targeting oncogenic WNT/beta-catenin signaling in therapy. Curr Drug Targets 9: 532-547, 2008.
17. Garber K: Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst 101: 548-550, 2009.
18. Shimizu Y, Demetris AJ, Gollin SM, et al: Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 52: 252-260, 1992.
19. Oertel M, Schastak SI, Tannapfel A, et al: Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. J Photochem Photobiol B 71: 1-10, 2003.
20. Knuth A, Gabbert H, Dippold W, et al: Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1: 579-596, 1985.
21. Saijyo S, Kudo T, Suzuki M, et al: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177: 61-71, 1995.
22. Purdum PP 3rd, Ulissi A, Hylemon PB, Shiffman ML and Moore EW: Cultured human gallbladder epithelia. Methods and partial characterization of a carcinoma-derived model. Lab Invest 68: 345-353, 1993.
23. Kiesslich T, Berlanda J, Plaetzer K, Krammer B and Berr F: Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan- and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci 6: 619-627, 2007.
24. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med 341: 1368-1378, 1999.
25. Berman DM, Karhadkar SS, Maitra A, et al: Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846-851, 2003.
26. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W and Nitsche A: Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313: 856-862, 2004.
27. Oberdanner CB, Kiesslich T, Krammer B and Plaetzer K: Glucose is required to maintain high ATP-levels for the energy-utilizing steps during PDT-induced apoptosis. Photochem Photobiol 76: 695-703, 2002.
28. Baradari V, Hopfner M, Huether A, Schuppan D and Scherubl H: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 13: 4458-4466, 2007.
29. Neureiter D, Zopf S, Dimmler A, et al: Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. Pancreatology 5: 387-397, 2005.
30. Zopf S, Neureiter D, Bouralexis S, et al: Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 31: 1391-1402, 2007.
31. Churg J and Prado A: A rapid Mallory trichrome stain (chromotrope-aniline blue). AMA Arch Pathol 62: 505-506, 1956.
32. Detre S, Saclani Jotti G and Dowsett M: A 'quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878, 1995.
33. Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B and Plaetzer K: Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol 25: 173-188, 2006.
34. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
35. Plaetzer K, Kiesslich T, Krammer B and Hammerl P: Characterization of the cell death modes and the associated changes in cellular energy supply in response to AlPcS4-PDT. Photochem Photobiol Sci 1: 172-177, 2002.
36. Behrens J and Lustig B: The Wnt connection to tumorigenesis. Int J Dev Biol 48: 477-487, 2004.
37. Mishra L, Shetty K, Tang Y, Stuart A and Byers SW: The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 24: 5775-5789, 2005.
38. Tokumoto N, Ikeda S, Ishizaki Y, et al: Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 27: 973-980, 2005.
39. Miranda-Carboni GA, Krum SA, Yee K, et al: A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev 22: 3121-3134, 2008.
40. Tang Y, Simoneau AR, Liao WX, et al: WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther 8: 458-468, 2009.
41. Settakorn J, Kaewpila N, Burns GF and Leong AS: FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 58: 1249-1254, 2005.
42. van de Wetering M, Sancho E, Verweij C, et al: The betacatenin/ TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250, 2002.
43. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL and Tallini G: Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158: 987-996, 2001.
44. Ashida K, Terada T, Kitamura Y and Kaibara N: Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 27: 974-982, 1998.
45. Sugimachi K, Taguchi K, Aishima S, et al: Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 14: 900-905, 2001.
46. Itatsu K, Zen Y, Ohira S, et al: Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int 27: 1174-1184, 2007.
47. Abraham SC, Lee JH, Hruban RH, Argani P, Furth EE and Wu TT: Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol 34: 902-910, 2003.
48. Brabletz T, Hlubek F, Spaderna S, et al: Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179: 56-65, 2005.
49. Moustakas A and Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520, 2007.
50. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z and Pinna LA: 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321: 1040-1044, 2004.
51. Dominguez I, Sonenshein GE and Seldin DC: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci 66: 1850-1857, 2009.
52. Gao Y and Wang HY: Casein kinase 2 Is activated and essential for Wnt/beta-catenin signaling. J Biol Chem 281: 18394-18400, 2006.
53. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D and Dominguez I: CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 274: 63-67, 2005.
54. Duncan JS and Litchfield DW: Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784: 33-47, 2008.